Despite the significant clinical outcome associated with FAAP20-mutated cancers, genetic screening for FAAP20 patient variants is very uncommon, warranting increased attention and testing of FAAP20’s expression status in aggressive cancers. The gene discussed is FAAP20; the disease is cancer.